Annals of Oncology

Papers
(The H4-Index of Annals of Oncology is 90. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-01-01 to 2026-01-01.)
ArticleCitations
425P Real-world treatment patterns and outcomes in patients with advanced gastric cancer in Japan1236
342eP Multiomic characterization of early and metastatic biliary tract cancer (BTC)1034
505eP Real-world efficacy of anlotinib in bevacizumab-treated gastrointestinal cancers833
501P Bayesian selection of lipidome dynamics features for a K-nearest neighbors (KNN) classifier model of tumor response in patients with advanced gastrointestinal (GI) adenocarcinoma undergoing syste598
114P Radiologist concordance and pathology correlation in non metastatic colon cancer (NMCC) staging588
307P AI-driven patient screening for clinical trials in pancreatic cancer: Integrating LLMs with tumor board meetings529
300P Clinical, pathological, and genomic biomarkers associated with early recurrence in resected localized pancreatic ductal adenocarcinoma (L-PDAC)508
327P Real world evidence of outcomes and treatment patterns for advanced biliary tract cancer in Saudi Arabia483
16P Early ctDNA decrease predicts survival in MSI metastatic colorectal cancer treated with immunotherapy476
139eP Real-world practice of MSI/MMR testing and treatment patterns in colorectal cancer: A nationwide survey in China (SUMMER study)448
251P Clinical outcomes of rectal squamous cell carcinoma in British Columbia, Canada434
92P Real-world evidence of a tissue-free ctDNA-based minimal residual disease (MRD) testing in colorectal cancer (CRC): Insights from an Indian cohort431
11P Practice patterns and 90-day treatment-related morbidity in early-stage cervical cancer364
Title Page362
CN14 Cancer prevention awareness among Croatian AYA population352
147P Chemo-immunotherapy with or without consolidative radiotherapy in extensive-stage small cell lung cancer: An initial report of clinical outcome and safety347
105P CDK4/6 inhibitors in hormone receptor-positive, HER2-negative, locally advanced breast cancer (LABC): Biological and clinical activity, and post-surgical approaches342
51P Novel platform combines pathology and transcriptomics for a multi-scale analysis and visualization of the breast tumor heterogeneity294
82P Obtaining microvesicles from T-lymphocytes using various methods of induction292
1290TiP A phase II multicenter, open label, non-randomized study of neoadjuvant and adjuvant treatment with IPH5201 and durvalumab in patients with resectable, early-stage (II to IIIA) non-small cell 284
166P Metabolomic prediction of breast cancer treatment toxicities267
332P Early prediction of residual cancer burden to neoadjuvant chemotherapy in breast cancer by longitudinal MRI-based multitask learning: A multicenter cohort study248
1310P Loratadine: A potential game-changer in lung cancer treatment with improved survival outcomes248
2335P Spatial whole exome sequencing reveals the genetic features of highly-aggressive components in lung adenocarcinoma246
1152P Association of immune-related adverse events (irAE) requiring glucocorticoids (GCs) with outcome and biomarkers in advanced cutaneous malignant melanoma (CMM) treated with immune checkpoint inhi243
179P Molecular tumor board directed treatment for patients with advanced stage solid tumors: A case-control study242
1890P Switch-maintenance therapy with nivolumab in TKI-sensitive patients with metastatic renal cell carcinoma (mRCC): Subgroup analysis for PD-L1 status of a randomized phase II study (NIVOSWITCH)224
1O CircIGF1R_0001 mediates platinum resistance in ovarian cancer that sensitive to PARP inhibitors via promoting PARP1 binding to DNA damage sites224
1905P Heterogeneity in tertiary lymphoid structures predicts the distinct prognosis and immune microenvironment of clear cell renal cell carcinoma214
14P Peripheral immune kinetics in survival prediction of small cell lung cancer patients treated with immune checkpoint blockade therapy209
2092P Bone loss in premenopausal Algerian women treated with chemotherapy for early-stage of breast cancer: Evaluation by DXA and identification of associated risk factors206
1590P Real-world gastric cancer (GC) in Latin America (LATAM) and Europe (EU)203
1176P Planned drug holidays during immunotherapy in advanced and metastatic melanoma patients: A nation-wide study198
1601P Relationship between CT and ultrasonography-based sarcopenia and hematologic toxicity in patients with cancer receiving chemotherapy196
878P INHBA is overexpressed in HPV-negative oropharyngeal squamous cell carcinoma and contributes to an aggressive phenotype196
1096P Prolonged follow-up confirms durability of favorable outcomes after neoadjuvant ipilimumab plus nivolumab in melanoma192
2067P Influence of psychiatric disorders on survival in patients with lung cancer: Real-world data188
CN69 Experiences of patients after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy: A qualitative study185
809P Mental and socioeconomic burden in endometrial and cervical cancer patients: A Swedish population-based study of survivorship175
1589P Systemic treatment strategies and outcomes of patients with peritoneal metastases of gastric origin175
CN55 The impact of psychosocial support on the overall health of cancer patients in the COVID-19 era174
1296P Neoadjuvant camrelizumab and apatinib in patients with resectable non-small-cell lung cancer: One-year update from a phase II trial169
1608P Albumin-myosteatosis gauge as a prognostic factor in patients with advanced pancreatic cancer undergoing first-line chemotherapy169
515P A MRI-based radiomics model for predicting the response to anlotinb combined with temozolomide in recurrent malignant glioma patients168
1232P Analytic analysis of PanSeer7, a targeted bisulfite sequencing assay for blood-based multi-cancer detection for cancer early detection and tissue-of-origin identification167
2173P Exploring the complex needs of older patients receiving targeted therapies and immune checkpoint inhibitors for renal and skin cancers at the Royal Marsden Hospital167
578P Tissue-resident microbiota characterization in colorectal cancer metastases162
577P Systematically assessing the intratissue microbiota in 937 patients with colorectal cancer160
1398P Hepatotoxicity in patients (pts) with KRASG12C-mutated non-small cell lung cancer (NSCLC) treated with sotorasib after prior immunotherapy (IO)159
1921MO Patterns of care, outcome and molecular landscape of PATZ1-rearranged sarcomas identifies two prognostic profiles: A cohort study from the French Sarcoma Group (FSG)156
MO60-4 Tryptophan is the prognostic factor in patients with unresectable pancreatic cancer154
2132P Unmet needs, quality of life, and financial toxicity in survivors of lung cancer148
1997P A study of sintilimab combined with anlotinib and chemotherapy as second-line or later therapy in extensive-disease small cell lung cancer146
1939P phase I clinical results of SQ3370, a doxorubicin-based click chemistry therapeutic in advanced solid tumor patients145
56P SLC34A2-ROS1 L2026M+G2032R confers resistance to ROS1 tyrosine kinase inhibitors in Ba/F3 cells through a reduced ATP binding pocket volume141
1991P Safety and effectiveness of surgery or radiotherapy after PD-L1 Inhibitor (TQB-2450) and chemotherapy induction therapy in patients with limited-stage small cell lung cancer: A phase II trial136
285O Prevalence of homologous recombination deficiency in ovarian, primary peritoneal, and/or fallopian tube cancer: Results from the international HALO study136
457P Disparities in receipt of CDK4/6 inhibitors with endocrine therapy as therapy for hormone receptor-positive, HER2-negative metastatic breast cancer in the real-world setting125
402O A randomized phase III trial of site-specific therapy guided by the 90-gene expression assay versus empiric chemotherapy in patients with cancer of unknown primary122
1651P Comparison of surgical outcome and prognostic factors between pancreaticobiliary and intestinal types of periampullary adenocarcinoma following pancreaticoduodenectomy122
365P Radiotherapy treatment outcomes and treatment compliance of nasopharyngeal cancer patients in Sabah: A retrospective analysis122
1677P Pancreatic enzyme replacement therapy improves survival in patients receiving nab-paclitaxel plus gemcitabine as first-line treatment for advanced pancreatic adenocarcinoma120
2272P Minimal DNA-methylation (DNAm) signatures for non-invasive tumor-agnostic estimation of tumor content (TC) and molecular subtype in patients (pts) with metastatic breast cancer (mBC)120
1723P Improving access to molecular tumour boards for complex genomic profiles: A healthcare policy from the Netherlands120
1122P Neutrophil/lymphocyte ratio and systemic inflammatory index as prognostic biomarkers in metastatic melanoma patients under immune checkpoint inhibitors: Could any of them be used?119
1593MO Combined early palliative care in patients with non small cell lung cancer: A randomised controlled trial in Chongqing, China115
22P Clinical significance of DNA damage response mutations in early stage NSCLC112
49P Circulating miRNA signatures to predict recurrence in patients with pathological complete response of triple-negative breast cancer110
1681P A retrospective real-world study for nimotuzumab plus postoperative adjuvant chemotherapy for resectable pancreatic cancer110
MO48-4 Efficacy and quality of life in blinatumomab treatment in patients with acute lymphoblastic leukemia: Systematic review109
121P PemiBil: Efficacy and safety of pemigatinib in advanced cholangiocarcinoma with FGFR2 fusions/rearrangements in real-world, results of multicentric French cohort from ACABI consortium106
1702P Real-world evidence contributions to European medicines agency’s safety and efficacy evaluations of oncology targeted therapies between 2018-2022106
2116P Preoperative body mass index, waist circumference, and mortality after major cancer surgery: A nationwide cohort study in South Korea103
907P Radiosensitivity signature in adenoid cystic carcinoma (ACC) of salivary glands origin is associated with ACC type II103
936P Triple oral metronomic chemotherapy (OMCT) versus physician choice chemotherapy after failure of platinum-based therapy in advanced head and neck squamous cell cancer (HNSCC): A phase III randomi102
971P Effect of preoperative frailty on surgical outcomes following hepatic resection for elderly patients with hepatocellular carcinoma: A multicenter retrospective cohort study from China102
MO68-4 A chemoproteoinformatics approach demonstrates that aspirin increases sensitivity to MEK inhibition by directly binding to RPS5101
2276P Regulation of major histocompatibility class-I gene methylation using DNA methyltransferase inhibitor and PD-L1 inhibitor in triple-negative breast cancer97
505P Neoadjuvant PD-1 inhibitor (tislelizumab) plus platinum–etoposide in patients with limited-stage small cell lung cancer: A phase II trial96
953P Tislelizumab plus regorafenib as second-line therapy for unresectable hepatocellular carcinoma (uHCC): A single-arm, phase II trial96
1707P Cancer drug prices in the US: Efficacy, innovation, clinical trial evidence, and epidemiology96
995P Real-world treatment patterns, survival and costs in advanced hepatocellular carcinoma (aHCC) in Ontario, Canada95
1673P Trajectories of immune-related serum proteins and quality of life in patients with pancreatic and other periampullary cancer: The champ study95
2293P Protumoral role of neutrophils and neutrophils extracellular traps (NETS) in non-metastatic gastroesophageal and rectal cancers95
2311P Population pharmacokinetic-pharmacodynamic modeling to inform optimal dosing strategies for GI-101, a novel fusion protein, targeting IL2βγR and CTLA495
201P A phase II study of serplulimab (a programmed death-1 inhibitor) with or without HLX04 (a bevacizumab biosimilar) for the treatment of advanced hepatocellular carcinoma93
329P Pulmonary function and lung fibrosis up to 12 years after breast cancer radiotherapy93
622P A prognostic and immune infiltration analysis of CCL26 in pan-cancer92
2028TiP Phase I, non-randomised, open-label, multi-centre dose escalation trial of BI 764532 (DLL3/CD3 IgG-like T cell engager [TcE]) + ezabenlimab (anti-PD-1 antibody) in patients (pts) with small ce91
195P Ferroptosis signatures in pancreatic ductal adenocarcinomas and their role in patient survival: A translational unsupervised clustering analysis90
1274P Early dynamics of circulating tumor DNA following curative hypofractionated radiotherapy related to disease control in lung cancer90
0.28802895545959